Multifaceted approaches modulate slow-wave activity as therapeutic interventions in mouse models of alzheimer's disease: drug-free therapy, pharmaceutical therapy and gene-therapy - alzheimer's…

Active Grant Awarded

Award ID
R56AG098813
Recipient
Awarding agency
Obligated
$617,796

Award facts

Assistance listing
93.866 Aging Research
Completion date 21% complete
Place of performance
West Roxbury, MA 02132, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Boston VA Research Institute, Inc. a grant of $617,796 on September 9, 2026, under the Aging Research program (CFDA 93.866). The award, Grant R56AG098813, funds a translational project on slow-wave activity as a therapeutic target in mouse models of Alzheimer's disease. The project pursues three independent aims: acoustic stimulation at the slow-wave frequency during wakefulness, pharmaceutical targeting of brain circuits that generate slow-wave activity, and chemogenetic modulation and gene therapy of the claustrum. In each aim, the work measures effects on brain clearance, reduction of amyloid-beta deposits in brain tissue, and cognitive performance on behavioral tasks. The program funds biomedical, social, and behavioral research on aging, with particular emphasis on preventing and treating Alzheimer's disease and related dementias. Performance runs from the September 9, 2026 award date through an ultimate completion date of August 31, 2027, with work performed in West Roxbury, Massachusetts. The source names no sub-recipients for this award.

Description

Multifaceted approaches modulate slow-wave activity as therapeutic interventions in mouse models of alzheimer's disease: drug-free therapy, pharmaceutical therapy and gene-therapy - alzheimer's disease (ad) is a devastating illness increasing in prevalence with no cure. In the last 12 years, basic and clinical work has revealed deep sleep washes the brain of toxins that cause ad. Electroencephalographic (EEG) brain waves that define deep sleep - "slow-wave activity" - precede, possibly coordinate, cerebrospinal fluid (CSF) washes promoting brain clearance. Yet, slow-wave activity has not been a major target for ad therapy. Slow-wave activity is regulated by circuits that connect the thalamus and the cortex; and by the claustrum, a thin long well-connected region enriched with the carboxypeptidase inhibitor called latexin. Slow-wave activity, the claustrum and latexin are all reduced in ad. This translational proposal in ad model mice is comprised of three independent specific aims, each using distinct methodologies to bolster slow-wave activity. Aim 1) acoustic stimulation at the slow-wave frequency during wakefulness. Aim 2) pharmaceutical targeting of brain circuits generating slow-wave activity. Aim 3) chemogenetic modulation and gene-therapy of the claustrum. In each aim we will assess the effectiveness of these interventions to 1) increase brain clearance, 2) reduce amyloid-Β (AΒ) deposits in brain tissue, 3) improve cognitive performance on behavioral tasks. Our preliminary data demonstrate feasibility and likelihood of successfully completing this project: 1) our ability to measure EEG and brain clearance simultaneously in vivo, in real time, and repeatedly, during records lasting >24H. 2) our ability to use an innovative acoustic stimulation to bolster slow-wave activity during wakefulness, and reduce AΒ in ad mice. 3) our ability to bolster slow-wave activity during non- REM by a pharmaceutical called Α3IA in ad mice. 4) resources to rigorously test the hypothesis that Α3IA bolsters slow-wave activity by stimulating the neurocircuits generating slow-wave activity. 5) selective stimulation of the claustrum by the excitatory chemogenetic construct HM3DQ to boost slow-wave activity. 6) our ability to design and acquire novel gene-therapy based constructs for expressing latexin selectively in the claustrum. 7) our ability to bolster slow-wave activity with gene-therapy mediated expression of latexin in the claustrum of ad mice. Each aim develops interventions that can be translated as therapies for ad. Aim 1 focuses on a cheap, scalable and non-invasive method for use in patients' homes. Aim 2 focuses on a drug with well-established molecular mechanisms which could enter clinical trials. Aim 3 uses gene therapy-based technologies to provide an avenue to treatment for those at high risk of ad. We also describe early markers preceding symptoms in ad mice, which could lead to screens for high risk of ad.

Quick answers

Who received award R56AG098813?

R56AG098813 was awarded to Boston VA Research Institute, Inc. by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award R56AG098813 worth?

$617,796 has been obligated on R56AG098813.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award